CMS Projects: Fewer Losses and Bigger Savings. That Only Works If the Sick Are Removed.
CMS forecasts fewer disenrollments than CBO and higher savings. Both hold only if the people removed are the expensive ones, which means the sick.
Legal & Policy
Lilly Can Sue the Sellers. It Can Only Ask the Payment Networks.
Six suits against small peptide sellers is not a strategy for a market spanning a hundred countries. It is a demonstration attached to an appeal.
Black Diamond Bought a Licence Instead of a Ruling, and Six Patents Stay Untested
These were not patents on a drug. They were patents on the methods used to find one, and Black Diamond has agreed to pay rather than test them.
Oman Is Offering Drug Manufacturers the One Thing Government Procurement Normally Destroys
Committing 30% of a health ministry’s requirement at agreed prices means deciding not to buy the cheapest product. Somebody is paying for that.
Washington Narrowed the Childhood Schedule, and the Insurer Backstop Quietly Stopped Being One
Washington Narrowed the Childhood Schedule, and the Insurer Backstop Quietly Stopped Being One
DuPont Spun Chemours Off in 2015. Eleven Years On, Both Are Named in the Same Order.
QuickCI read/Legal & Policy/Medtech DuPont Spun Chemours Off in 2015. Eleven Years On, Both Are Named in the Same Order. Athithi Verma· 11 August 2026· 3 min read· Synopulse Chief Judge Renée Marie Bumb of the US District Court for New Jersey approved settlements worth more than $2.5 billion on 7 August 2026, resolving claims … Read more
The EPO Revoked BMS’s 480mg Opdivo Patent Because the Trial Behind It Dosed by Weight
BMS claimed a 480mg flat dose. The only clinical example in its filed application dosed by weight. The EPO revoked the patent on added matter.
AstraZeneca Announced Nothing. The Market Charged It $24bn Anyway.
AstraZeneca closed 9% down on an unconfirmed report of Bristol Myers talks. Roughly $24bn gone, on a conversation neither company will admit to.
The 340B Rebate Pilot Is Back at Under 5.5% of Sales, Rebuilt to Survive the Court That Killed It
HRSA restarted the 340B rebate pilot at under 5.5% of sales, wrapped in 21 pages of answers to the court that vacated the first one.
Congress Exempted the Medically Frail. The Coding System Cannot Find Them.
Fewer than 500 of 10,000 rare diseases have an ICD-10 code. The Medicaid frailty exemption is verified against codes most patients never had.